There has been a quiet but meaningful change in the governance structure of Boryung Co., Ltd., a domestic pharmaceutical company. On 1 May, Boryung Holdings absorbed Boryung Partners, achieving a unified governance structure. Once the merger is completed, the 21.1% stake in Boryung held by Boryung Partners will be transferred to Boryung Holdings, which will then become the sole holding company of Boryung with a 50.8% stake. As soon as the regulatory approval process is completed, Boryung is scheduled to officially transition to a single holding-company structure that meets the requirements of a holding company under the Fair Trade Act. On the surface, it is a simple merger in which Boryung Holdings and Boryung Partners are combined into one, but it reflects Boryung’s direction toward establishing a mature governance structure.

“Two control towers become one”… Integration of a dual structure

Boryung had previously maintained two entities at the top of its governance structure. Boryung Holdings and Boryung Partners each held stakes in Boryung and stood at the apex of the governance framework. Operating separate entities led to the accumulation of administrative inefficiencies and the dispersion of decision-making, inevitably slowing the execution speed of company-wide strategies. Management costs also could not avoid duplication. Corporate governance experts share the view that “Boryung’s existing structure was an unnecessary duplication in both cost and administration.”

Expectations are that this structural inefficiency will be largely resolved through the merger. By integrating the two entities into a single holding company, Boryung aims to unify the decision-making system, eliminate overlapping management structures, and enhance execution capabilities.



Simplified equity structure, foundation for transparency

One of the key benefits of transitioning to a holding company structure is securing visibility into the equity structure. In complex multi-layered structures, capital flows and decision-making paths are more likely to become opaque. For investors and external stakeholders, the ongoing challenge has been the difficulty of identifying “who makes what decisions under what authority.”

With the transition to a single holding company system, decision-making channels become clearer and the responsibility for each decision is more distinctly defined. Shareholders and investors will be able to clearly track capital flows and management decisions through the holding company. The market is paying particular attention to the fact that the structure has been streamlined so that a single holding company controls a listed entity, creating a foundation for Boryung’s business performance and growth potential to be directly reflected in its corporate value. This is a factor directly linked to corporate credibility in the current market environment, where ESG (environmental, social and governance) standards are being strengthened.

Experts in corporate governance note that “the holding company structure is an effective model not only for enhancing management efficiency but also for establishing a framework subject to external oversight,” adding that “governance transparency improves meaningfully when multiple entities with holding-company functions are integrated.”

Boryung also stated, “Simplifying the equity structure will strengthen the transparency, clarity and accountability of management decision-making,” emphasizing that “enhancing credibility from the perspective of stakeholders is one of the key expected benefits of this transition.”

At the same time, practical considerations related to meeting legal requirements also played a role in this transition. As Boryung’s asset base expanded, it met the designation criteria for a holding company under the Fair Trade Act, making it a natural step to establish a legal and institutional framework in line with this status.

Focus on the ‘original role of a holding company’ after the transition

Boryung’s task after the completion of the merger is clear: to consistently maintain a group-wide strategic direction based on the management efficiencies secured under the new single holding-company structure. In the pharmaceutical industry, there is a growing recognition that the role of a holding company must go beyond simple equity ownership. Practical value-creation functions are expected, such as optimizing resource allocation to subsidiaries, managing risks in new business ventures, and coordinating R&D portfolios.

Boryung currently has a diverse business portfolio built around chronic disease medicines centered on the Kanarb family and cell-toxic anticancer drugs led by “Taxotel” (ingredient name: docetaxel), for which it signed an acquisition agreement last year. Backed by its business competitiveness, the company posted strong consolidated results in the first quarter of this year, with sales of KRW 255.4 billion and operating profit of KRW 20.2 billion. These figures represent growth of 6.2% and 84.7%, respectively, compared with the same period a year earlier.

How synergies among these businesses will be realized under a single holding-company structure is expected to become the core of Boryung’s future strategy. Boryung is pursuing a mid- to long-term growth strategy based on three pillars: expansion of its global business and investment in strategic new businesses, both underpinned by a stable cash flow from its domestic pharma operations.

Specifically, in the domestic pharmaceutical business, the company is focusing on consolidating its market leadership in the chronic metabolic disease segment, while continuously expanding its pipeline in the oncology segment within the domestic market.

In addition, Boryung is expanding into global markets based on its contract development and manufacturing organization (CDMO) operations and the supply of cell-toxic anticancer drugs. In September last year, Boryung signed an acquisition agreement with global pharmaceutical company Sanofi for the global business of the cell-toxic anticancer drug Taxotel and is accelerating preparations for in-house production.

The rights acquired by Boryung include all rights such as domestic and overseas marketing rights, distribution rights, regulatory approvals, manufacturing rights, and trademark rights. This agreement is significant in that a Korean pharmaceutical company has acquired the original docetaxel product, which is widely prescribed worldwide. Following the regulatory approval process, Boryung plans to directly manufacture, distribute, and sell the original medicine in the global market, targeting 19 countries. The company is also pursuing a global CDMO business based on its own manufacturing infrastructure.

Third, Boryung is continuing to invest in new businesses for future growth. The company currently regards space life science as a long-term core growth engine and is continuing to invest in research infrastructure.

It is in the process of building a foundation that will allow its accumulated pharmaceutical assets and research capabilities on Earth to be tested and advanced in low Earth orbit environments, with the long-term goal of securing a new experimental setting for pharmaceutical and life science research.

The single holding-company structure is expected to play a key role in improving the speed and accuracy of decision-making in balancing and prioritizing these three pillars and allocating resources where they are most needed. In particular, given Boryung’s current focus on implementing a full-fledged global strategy and building a space healthcare platform as future growth engines, a clear decision-making structure is expected to become critical infrastructure that will determine the speed and quality of new business execution.

The industry views this transition to a holding company not merely as a short-term effort to improve management efficiency, but as a process of establishing a structural foundation for the company’s next stage of growth. Above all, the merger is significant not simply as a reorganization of the governance structure, but as the establishment of transparent and efficient governance that can be accepted by employees and the market for the execution of mid- to long-term growth strategies and sustainable growth.

Popular News